Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Nivolumab / opdivo for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma as of February 2023

MARA Rating Company December 16, 2025

Nivolumab for neoadjuvant treatment of resectable non-small-cell lung cancer as of March 2023

MARA Rating Company December 16, 2025

Nivolumab / ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency as of May 2025

MARA Rating Company December 16, 2025

Nivolumab / relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over as of February 2024

MARA Rating Company December 16, 2025

Kesimpta / ofatumumab for treating relapsing-remitting multiple sclerosis as of May 2021

MARA Rating Company December 16, 2025

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy as of May 2023

MARA Rating Company December 16, 2025

Olaparib for treating hormone-relapsed metastatic prostate cancer with BRCA1 or BRCA2 mutations that has progressed after a newer hormonal treatment as of May 2023

MARA Rating Company December 16, 2025

Lagevrio / molnupiravir for treating COVID-19 as of April 2025

MARA Rating Company December 16, 2025

Momelotinib / omjjara for treating myelofibrosis-related splenomegaly or symptoms as of March 2024

MARA Rating Company December 16, 2025

Lunsumio / mosunetuzumab for treating relapsed or refractory follicular lymphoma as of May 2023

MARA Rating Company December 16, 2025